Starling Oncology, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Starling Oncology, Inc. (DFPH) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $9.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-12
- Starling Oncology, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $9.05M, a 25.18% increase from fiscal 2024.
- Starling Oncology, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $7.23M, a 46.58% decline from fiscal 2023.
- Starling Oncology, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $13.54M, a 8.87% decline from fiscal 2022.
- Starling Oncology, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $14.86M, a 114.03% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 2 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $9.05M 10-K · filed 2026-03-12 | ||
| 2024-12-31 | $7.23M 10-K · filed 2026-03-12 | ||
| 2023-12-31 | $13.54M 10-K · filed 2025-03-26 | ||
| 2022-12-31 | $14.86M 10-K · filed 2024-03-28 | ||
| 2021-12-31 | $6.94M 10-K · filed 2023-03-16 | ||
| 2020-12-31 | $3.60M 10-K · filed 2022-03-11 | $101.68K 10-K · filed 2021-03-30 | |
| 2019-12-31 | $483.00 10-K/A · filed 2021-12-14 |